Financial Performance & Growth - The company reported a 39% profit growth [30] - Underlying EBITDA for 1H26 is projected to be $14 million to $16 million [30, 56] - Underlying EBITDA increased by 20% to $23.5 million from $19.5 million [43] - Underlying EBITDAR Per Care Bed increased by 13% to $27.9K from $24.7K [45] - Total FY25 cash dividend was 1.45cps, compared to 0.70cps in FY24 [45] Expansion & Acquisitions - Acquired St Allisa, a 109-bed care home, through a leaseback arrangement [24, 27, 30] - Acquired 51% of Cibus Catering Limited, resulting in a $4.1 million revenue uplift [30] - Pursuing capital-light expansion focused on new-build 100-bed care homes leased from private investors [28] Operational Efficiency & Staffing - Company-wide staff turnover decreased by 30% year-on-year, reaching a record low [48] - 86% of care homes audited in FY25 received 4-Year Certification [49] - Average occupancy is trending upwards, reaching approximately 95% [50] - The company acquired 920,000 shares for $280,000, with an average buyback price of 30.4cps [39, 40]

Approved for release by the Board of Directors For personal use only Executive Summary EOS continues to commercialise IP with this A$125m contract. Laser weapon technology is a significant growth opportunity for EOS Drone warfare is driving an urgent market need Directed energy weapons are a critical defence layer High Energy Laser Weapon Investor Update Webinar – 7 August 2025 Dr. Andreas Schwer, Managing Director & Chief Executive Officer Clive Cuthell, Chief Financial Officer & Chief Operating Officer EO ...

Dimerix Overview - Dimerix is developing DMX-200, a lead drug candidate in Phase 3 clinical trial for focal segmental glomerulosclerosis (FSGS)[14] - FSGS is a rare kidney disease with no approved treatments, leading to irreversible kidney damage, dialysis, transplant, or death[14] - Dimerix has secured orphan drug designation for DMX-200, providing regulatory, marketing exclusivity, and pricing benefits in key territories[14] - Dimerix has licensing partners across key territories for DMX-200[14] Financial Achievements and Partnerships - Dimerix has received over AU$65 million in total payments to date[14,54] - Licensing deals are collectively valued up to approximately AU$1.4 billion in total upfront and potential milestone fees plus royalties[14,53] - A 3rd development and license agreement for DMX-200 in Japan is valued up to ¥10.5 billion (~AU$107 million) in upfront/milestones, plus royalties[17] - A 4th license agreement for DMX-200 in the United States is valued up to US$590 million (~AU$940 million) in upfront/milestones, plus royalties[17] Clinical Trial and Regulatory Progress - The FDA confirmed proteinuria as an acceptable endpoint for full marketing approval in the US[17] - The ACTION3 study has enrolled 225 patients, with 52 patients enrolled in the Open Label Extension Study as of August 5, 2025[33] - The Phase 3 trial aims to recruit a total of approximately 286 patients[33] - Dimerix held a positive Type C meeting with the FDA in March 2025 regarding proteinuria trial endpoints for full approval and potential accelerated approval for DMX-200[41] Market Opportunity - The estimated global incidence of FSGS is over 200,000 per year[61] - The estimated incidence of FSGS per year across all Dimerix licensed territories is approximately 50,071[61]

Market Opportunity and Unmet Needs - Achieve Life Sciences has a unique opportunity to address a market of up to 50 million Americans who use tobacco with Cytisinicline[6] - Nicotine dependence is a public health crisis costing billions of dollars[6] and there are ~29 million US smokers with few treatment options[12] - Approximately 60% of adult e-cigarette users want to quit[14], with ~17 million US adults reporting e-cigarette use[16] - An estimated $11 Billion Rx opportunity exists in the market[46] Cytisinicline's Potential and Clinical Data - Cytisinicline is presented as the first potential new nicotine dependence treatment option in nearly 20 years[6, 18] - ORCA-2 and ORCA-3 trials showed strong results in smoking cessation, demonstrating efficacy, tolerability, and craving reduction[22] - In the 12-week Cytisinicline Treatment, the quit rate is 32.6% compared to 7% in the placebo group[23] - In the 6-week Cytisinicline Treatment, the quit rate is 25.3% compared to 4.4% in the placebo group[23] - Phase 2 ORCA-V1 trial showed a 2.6x (p=0.035) increased likelihood of quitting vaping with cytisinicline[39] Commercialization Strategy - The company anticipates filing a Smoking cessation NDA with launch expected in 2H26[6] - A focused launch strategy will leverage innovative, data-driven solutions to drive adoption and future growth[7] - The company will focus on high-volume prescribers and engaged quitters[48] - The company will target the varenicline market share, which peaked at ~2.8M Rx (75% in U S market - $800M)[51]

For personal use only 2025 AUSTRALIAN RICE CONFERENCE Shaping the future Paul Serra SunRice Group CEO August 2025 2 0 2 5 A U S T R A L I A N R I C E C O N F E R E N C E Important notice & disclaimer This presentation has been prepared by Ricegrowers Limited (SunRice) and provides summary information only. SunRice has prepared this presentation in good faith believing the statements made in it to be true as at the date of the presentation. SunRice is not otherwise warranting the accuracy of the information ...

For personal use only Bioshares Annual Conference Q&A presentation Hobart August 7, 2025 ® Xanamem is a registered trademark of Actinogen Medical Limited Disclaimer For personal use only Bioshares Q&A August 7, 2025 2 • This presentation has been prepared by Actinogen Medical Limited. ("Actinogen" or the "Company") based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make a ...

Commercialising Next -Generation Laser Enrichment Technology Equity Raising Presentation | August 2025 This Presentation has been prepared by Silex Systems Limited ABN 69 003 372 067 (Silex or Company) (ASX: SLX) (OTCQX: SILXY) and is dated 7 August 2025. The information contained in this Presentation is current as at the date of this Presentation or such earlier date as specified in this Presentation. This Presentation has been prepared in connection with the Company's proposed equity raising (Offer) of ne ...

Capital Raising Presentation 7 August 2025 NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES For personal use only ASX: LTR | ltresources.com.au NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES Important Information IMPORANT INFORMATION NOTICE AND DISCLAIMERS This investor presentation (Presentation) is dated 7 August 2025 and has been prepared by Liontown Resources Limited (ACN 118 153 825) (ASX: LTR) (Liontown or the Company). By accepting this Presentation, you represent and warrant that you are e ...

This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws, including any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management, including for future operati ...

Q2 2025 Financial Performance - Adjusted EPS reached $5.13, a 13% year-over-year increase, or 17% on a constant macro basis[10] - Revenues totaled $1.102 billion, up 13% year-over-year[10] - Adjusted EBITDA was $621 million, a 12% year-over-year increase[10] - The company reported organic revenue growth of 11%[10] - Revenue retention improved to 92.3%[10] Segment Performance - Corporate Payments revenue grew by 18%[10] - Vehicle Payments organic revenue growth was 9%[16] - Lodging Payments experienced a decline of 2%[16] - Other segments, including Gift and Payroll Cards, grew by 18%[16] Liquidity and Capital Allocation - Liquidity as of June 30, 2025, was approximately $3.5 billion[23] - Adjusted EBITDA was reported as $621 million[26] - Free cash flow generated was $366 million[26] - The company's leverage ratio was 2.53x[23] 2025 Guidance - The company projects second-half adjusted EPS to accelerate to $11.40, an 18% increase over the first half of 2025[32] - Organic revenue growth in the second half is expected to be 10%[32]